Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 17, 2025 05:21 ET | Source: Digbi Health

Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs

PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
November 15, 2024 16:00 ET | Source: INVENTIVA

Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2

Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...
November 15, 2024 16:00 ET | Source: INVENTIVA

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
November 12, 2024 16:05 ET | Source: Fractyl Health, Inc.

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
September 24, 2024 07:00 ET | Source: Fractyl Health, Inc.

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 03, 2024 07:00 ET | Source: Fractyl Health, Inc.

Fractyl Health to Participate in Upcoming September Investor Conferences

Fractyl Health to Participate in Upcoming September Investor Conferences
August 14, 2024 16:05 ET | Source: Fractyl Health, Inc.

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 16:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
April 01, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
January 05, 2024 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist

Next Page keyboard_arrow_right